Welcure Drugs & Pharmaceuticals Ltd Stock Analysis

BSE: 524661 | NSE: | Trading | Small Cap

BSE Share Price Jan 18, 18:01
11.43 0.54 (4.96%)

DeciZen - Make an Informed Decision on Welcure Drugs&Pharma

M-Cap below 100cr DeciZen not available

10 Year X-Ray of Welcure Drugs&Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide
Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
ROCE % 231.6%-14.4%-3.7%-7.7%-274.5%108.8%-65.6%18.1%-49.1%131.8%-
Value Creation Index NA-2.0-1.3-1.6-20.66.8-5.70.3-4.58.4-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 0000.10.10.10.10.10.10.10
YoY Gr. Rt. %-NA33.3%25%100%-10%-44.4%60%0%62.5%-
Adj EPS -0.10000.10-00-000
YoY Gr. Rt. %-NA-100%NANA-66.7%-150%NANANA-
BVPS (₹) -0.1-0.1-0.1-0.1000000.11.1
Adj Net Profit -0.10000.100000.10
Cash Flow from Ops. -0.2000-0.100000-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales NA5.4%37.5%62.5%
Adj EPS NA-7.8%NANA
BVPS 043.144.2500
Share Price 22.4% 27.3% 173.3% 414.9%

Key Financial Parameters

Performance Ratio Colour Code Guide
Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity % 232.3-14.4-3.6-7.6-274.3108.6-65.817.8-49.5131.70
Op. Profit Mgn % 0-25.3-27.16.932.430.9-412.9-11.641.30
Net Profit Mgn % 039.57.811.685.630.8-38.84.9-11.441.30
Debt to Equity 00000000000
Working Cap Days 025534528601095976610
Cash Conv. Cycle 00000000000

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 37.51%

Return on Equity has declined versus last 3 years average to 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Welcure Drugs & Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 0 -1.3
TTM Sales (₹ Cr.) 0 0.4
BVPS (₹.) 1.1 0
Reserves (₹ Cr.) -12 -13
P/BV 10.84 0.00
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 1.87 / 12.08
All Time Low / High (₹) 0.36 / 40.00
Market Cap (₹ Cr.) 15.4
Equity (₹ Cr.) 13.5
Face Value (₹) 10
Industry PE 82.5

Management X-Ray of Welcure Drugs&Pharma :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes

News

About Welcure Drugs & Pharmaceuticals Ltd

Welcure Drugs & Pharmaceuticals Ltd. (WDPL)  was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992.

Welcure is an Internationally ISO 9001:2000 and WHO-GMP Certified Company. It has to its credit the most modern and sophisticated manufacturing facilities of International Standards which include ultramodern plant, machinery and equipment, own R & D, in house testing laboratory and captive power generation.

Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups.  The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals.  The products of the company have already been well accepted in the domestic markets and the Company has an established customer base.

In March 2000 WDPL entered into a five-year agreement with Bihar Drugs and Chemicals Ltd (BDCL), a subsidiary of Bihar State Pharmaceutical and Chemical Development Corporation Ltd, for manufacturing various pharmaceutical pro ducts (both generic as well as branded) for the latter on loan licence basis. WDPL manufactures the drugs in tablet, capsule and syrup form at its facilities situated in Bhiwadi (Rajasthan).

The Company’s principal activity is to manufacture pharmaceutical products. The products of the Company include tablets, capsules, liquid orals and dry syrups.

Product range of the company includes:

Welcure manufactures a large variety of pharmaceutical formulations, covering almost all ailments, about 250 in numbers. Some of our known products include:

  • Brucure
  • Diclo-plus, Dimcinplus
  • Nimesulide
  • Nimagyltd (tongue dissolvent)
  • Ibucure & Relaxon Forte
  • Coldrest, Alert10004 Coldhistex
  • Cezen & Cezen Forte, Cezen CD
  • Kuffwel
  • X-Dryl, X-Dryl Forte
  • Renact DM
  • Renact DC
  • Diaroban
  • Welcee (Chewable Tab.)
  • Calbiplex
  • Wormicide
  • X-Clox
  • Weloxy-L
  • Welquin
  • Nortin, Cipcin-TNZ
  • Sarvo
  • B-Rest
  • Lopcure
  • Rifampicin, Ethambutol, Rifa-Z
  • Weloxy-P,Amicure-P
  • Norkid
Read More Read Less